Pet Cancer Therapeutics Market report provides key enumeration on the Market status of the Pet Cancer Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Pet Cancer Therapeutics industry. It delivers important information to identify and analyse the market need, market Growth and competition.
The global Pet Cancer Therapeutics Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Pet Cancer Therapeutics Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Overview
Cancer therapies for pets are new drug molecules with a great promise for reducing cancer’s effects and providing complete cancer care with minimal side effects. The goal of cancer treatments for dogs is to permanently eliminate malignant cells. Based on the kind of cancer, stage, and form of the disease, the veterinarian may prescribe a specific treatment plan, such as targeted therapy, combination therapy, or chemotherapy. The global pet cancer therapeutics market expansion is projected to be accelerated by scientists’ continuous research initiatives for the creation of innovative formulations and treatments. Scientists at the University of Veterinary Medicine are investigating the genetic basis of cancer growth in canine cell lines, claiming that the advent of tailored treatments would transform modern cancer therapy.
The global pet cancer therapeutics market was worth US$ 183.3 million in 2017 and is anticipated to grow at a 7.7 percent CAGR during the forecast period.
Drivers
In the coming years, an increase in the number of research funds to introduce various anti-cancer medicines for veterinary cancer therapy is projected to be a significant driver boosting the global pet cancer therapeutics market. The Blue Buffalo Foundation awarded the Animal Cancer Foundation (ACF) a $1 million grant in 2017 to encourage comparative oncology research, with the goal of studying commonalities between naturally occurring malignancies in people and pets and finding effective treatments in both species.
Additionally, organizations such as the PetCure Oncology, Veterinary Cancer Society, Animal Cancer Foundation, and Petco Foundation are conducting cardiology studies such as the canine cancer genome project to help comprehend the genetic makeup of cancer tumors in animals in order to find directed prescription drugs with the lowest toxic doses.
The rising prevalence of cancer necessitates the adoption of approved novel therapies that have been shown to be immensely effective in the treatment of cancers in pets, boosting the global pet cancer therapeutics over the forecast period. Dogs and cats have a greater frequency of cancers than people, according to a 2015 research by Fetch a Cure. According to a research released by the Animal Cancer Foundation in 2017, around 25 percent of all dogs will acquire a tumor at some time in their lives. Moreover, the rising number of relapsed cancer rates, as well as the availability of relapsed/refractory therapies combined with veterinarian recommendations, are projected to boost market revenue. According to a research published in 2015 by petMD, LLC, around 95 percent of dogs treated with lymphoma using chemotherapy regimens and traditional therapies are likely to develop disfigurement. In 50 percent of dog species, the remission lasts shorter than 15 months. Tanovea-CA1, a new chemotherapeutic medication developed by VedDC, Inc., was provisionally authorized by the FDA in 2017 as a first-line therapy for dogs with relapsed/refractory lymphoma and canine lymphoma.
Restraints
Additional therapeutic techniques such as herbal medicines and homoeopathy are becoming more popular, and side effects such as diarrhea, musculoskeletal problems, anorexia, and the high cost of pet cancer therapy are limiting the global pet cancer therapeutics market development.
Competitive Landscape
Key companies contributing in the global pet cancer therapeutics market are Morphogenesis, Inc., Zenoaq, AB Science, Aratana Therapeutics, Inc., Zoetis, Oasmia Pharmaceuticals AB, Rhizen Pharmaceuticals SA, Regeneus Ltd., Karyopharm Therapeutics, Inc., and VetDC, Inc..
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1284
Reasons to Purchase this Report
• Current and future of global Pet Cancer Therapeutics Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
About Us
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact Us
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837